Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Purdue Pharma.

    Client Virtual Booth

    PURDUE PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Purdue Pharma
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    Purdue Pharma Canada, 575 Granite Court, Pickering, ON Canada L1W 3W8
    Telephone
    Telephone
    1. 905-420-64002. 1-800-387-5349
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://purdue.ca/en/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

    Details:

    The grant will be used for the evaluation of nalmefene hydrochloride (HCl) injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects.


    Lead Product(s): Nalmefene Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Nalmefene HCl-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: The University of New Mexico

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing March 27, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Harm Reduction Therapeutics to Receive Additional Funding for its Low-Cost Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma

    Details:

    The proceeds will be used to fund commercial readiness for HRT’s low-cost over-the-counter (OTC) intranasal naloxone spray, tradename RiVive. Naloxone is an opioid antagonist rescue medication used to reverse the effects of a life-threatening opioid overdose.


    Lead Product(s): Naloxone Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Rivive

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: Harm Reduction Therapeutics

    Deal Size: $29.9 million Upfront Cash: Undisclosed

    Deal Type: Financing March 21, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Purdue Pharma Introduces Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) in the U.S. for the Treatment of Known or Suspected Overdose with Natural or Synthet...

    Details:

    Nalmefene is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose.


    Lead Product(s): Nalmefene Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Nalmefene Hydrochloride- Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 21, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Harm Reduction Therapeutics to Receive Additional Funding for the Development of its Over-the-Counter Opioid Overdose Reversal Medication from Purdue Ph...

    Details:

    The additional funding approved today will help HRT continue its work toward making OTC naloxone nasal spray available to the public. HRT plans to file a New Drug Application for naloxone nasal spray with FDA in 2022.


    Lead Product(s): Naloxone Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Revive

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: Harm Reduction Therapeutics

    Deal Size: $17.5 million Upfront Cash: Undisclosed

    Deal Type: Financing March 23, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Purdue Pharma L.P. to Provide Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal in Emergency Medicine Settings

    Details:

    FDA recently approved ANDA for nalmefene hydrochloride Injection, an opioid antagonist indicated for reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in management of known or suspected opioid overdose.


    Lead Product(s): Nalmefene Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Nalmefene Hydrochloride-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 17, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FDA Approves Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) for the Treatment of Known or Suspected Opioid Overdose with Natural or Synthetic Opioids

    Details:

    FDA has approved ANDA for Nalmefene hydrochloride injection, an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, induced by either natural or synthetic opioids, and in management of known suspected opioid overdose.


    Lead Product(s): Nalmefene Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Nalmefene Hydrochloride-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 23, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FDA Grants Priority Review for Nalmefene HCI Injection

    Details:

    Injectable nalmefene, an opioid antagonist designed to reverse opioid overdose, may be another treatment option to help address the growing and continuing crisis of opioid overdose deaths, including those due to fentanyl and other synthetic opioids.


    Lead Product(s): Nalmefene Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search